Frequently Asked Questions
We help medtech, digital health and pharmaceutical companies build the clinical, economic and value evidence needed for public funding through the MBS, the Prescribed List and the PBS. We cover the journey from evidence generation through to MSAC, MDHTAC and PBAC submissions, so sponsors reach a funding decision without unnecessary rework.
PBAC assesses medicines for listing on the PBS. MSAC assesses medical services, including therapeutic procedures and diagnostic tests, for MBS funding. MDHTAC advises on medical devices and human tissue products for the Prescribed List, which sets the benefits private health insurers pay. Each committee has its own evidence expectations and timelines, so a pathway-specific strategy is required.
It depends on the pathway and how mature the evidence is. PBAC meets three times a year (March, July and November) plus intracycle meetings. MSAC also meets three times a year (March, July and November). The Prescribed List is updated on 1 March, 1 July and 1 November each year, and MDHTAC has its own assessment timeframes. A weak submission can add six to twelve months through resubmission, so getting the evidence right the first time is what saves sponsors the most time.
Earlier than most companies think: ideally while studies are being designed (Phase 2/3 for medicines, or the pivotal clinical study stage for devices and diagnostics). Building health economic inputs into the study means the evidence is already fit for MSAC, Prescribed List or PBAC requirements, rather than retrofitting a model onto data that was not built for it.
Our team includes three former PBAC and MSAC evaluators, so we know how submissions are read and challenged from the assessment side. That shapes how we prepare every submission. It is paired with decades of combined HTA experience and hundreds of reimbursement submissions.
Yes. We advise digital health and AI-enabled technology companies on evidence needs, funding pathways and value demonstration. As an ANDHealth industry partner, we also support companies in its accelerator and commercialisation programs.
Yes. We deliver market access and reimbursement workshops, webinars and advisory sessions for founders, accelerators and industry groups. Previous workshops delivered for AUScelerate, ISPOR and Cicada Innovations.